Cargando…

Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations

INTRODUCTION: This phase I study explored the immunogenicity and reactogenicity of accelerated, Q7 fractional, intradermal vaccination regimens for COVID-19. METHODS: Participants (n = 60) aged 18-60 years, naïve to SARS-CoV-2 infection or vaccination, were randomly allocated into one of four homolo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niyomnaitham, Suvimol, Atakulreka, Suparat, Wongprompitak, Patimaporn, Copeland, Katherine Kradangna, Toh, Zheng Quan, Licciardi, Paul V., Srisutthisamphan, Kanjana, Jansarikit, Laddawan, Chokephaibulkit, Kulkanya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886662/ https://www.ncbi.nlm.nih.gov/pubmed/36733395 http://dx.doi.org/10.3389/fimmu.2022.1080791

Ejemplares similares

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
por: Niyomnaitham, Suvimol, et al.
Publicado: (2022)

Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial
por: Niyomnaitham, Suvimol, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults
por: Assantachai, Prasert, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
por: Chayachinda, Chenchit, et al.
Publicado: (2023)

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac(®), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
por: Chatsiricharoenkul, Somruedee, et al.
Publicado: (2022)

Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study
por: Niyomnaitham, Suvimol, et al.
Publicado: (2022)

Bioequivalence Study of 100-mg Cilostazol Tablets in Healthy Thai Adult Volunteers
por: Chatsiricharoenkul, Somruedee, et al.
Publicado: (2019)

Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study
por: Sirijatuphat, Rujipas, et al.
Publicado: (2022)

Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers
por: Angkasekwinai, Nasikarn, et al.
Publicado: (2022)

Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac
por: Nantanee, Rapisa, et al.
Publicado: (2022)

Methods for predicting vaccine immunogenicity and reactogenicity
por: Gonzalez-Dias, Patrícia, et al.
Publicado: (2019)

The Immunogenicity of Fractional Intradermal Doses of the Inactivated Poliovirus Vaccine Is Associated With the Size of the Intradermal Fluid Bleb
por: Bibby, Jack, et al.
Publicado: (2017)

Distinct roles for nitric oxide in resistant C57BL/6 and susceptible BALB/c mice to control Burkholderia pseudomallei infection
por: Breitbach, Katrin, et al.
Publicado: (2011)

Immunogenicity and Reactogenicity in Q Fever Vaccine Development
por: Fratzke, Alycia P., et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
por: Gonen, Tal, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV
por: Motta, Edwiges, et al.
Publicado: (2023)

Reactogenicity and immunogenicity of the intradermal administration of BNT162b2 mRNA vaccine in healthy adults who were primed with an inactivated SARS-CoV-2 vaccine
por: Temtanakitpaisan, Yutthapong, et al.
Publicado: (2022)

Can reactogenicity predict immunogenicity after COVID-19 vaccination?
por: Hwang, Young Hoon, et al.
Publicado: (2021)

Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review
por: Das, Swarnali, et al.
Publicado: (2022)

Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
por: Mahallawi, Waleed H., et al.
Publicado: (2021)

Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
por: Lee, Jisun, et al.
Publicado: (2023)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis
por: Karakizlis, Hristos, et al.
Publicado: (2022)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
por: Bauernfeind, Stilla, et al.
Publicado: (2021)

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
por: Sablerolles, Roos S.G., et al.
Publicado: (2022)

Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study
por: Yegorov, Sergey, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults
por: Wu, Yufei, et al.
Publicado: (2023)

Phylogenetic analysis of two new complete genomes of the hepatitis E virus (HEV) genotype 3 from Thailand
por: Chanmanee, Tipsuda, et al.
Publicado: (2020)

Case Report: Reemerging Paragonimiasis in Umphang District, Thailand
por: Hanprom, Jiranat, et al.
Publicado: (2023)

Immunogenicity of a Two-Dose Human Papillomavirus Vaccine Schedule in HIV-Infected Adolescents with Immune Reconstitution
por: Rungmaitree, Supattra, et al.
Publicado: (2022)

Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine
por: Thisyakorn, Usa, et al.
Publicado: (2014)

Data on immunogenicity and reactogenicity to COVID-19 vaccination among patients receiving maintenance dialysis
por: Karakizlis, Hristos, et al.
Publicado: (2022)

Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in mice
por: Maciel, Milton, et al.
Publicado: (2019)

Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings
por: Niyomnaitham, Suvimol, et al.
Publicado: (2014)

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study
por: Naranbhai, Vivek, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study
por: Hyun, Hakjun, et al.
Publicado: (2022)

Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants
por: Niyomnaitham, Suvimol, et al.
Publicado: (2023)

Immunologic hypo- or non-responder in natural dengue virus infection
por: Perng, Guey Chuen, et al.
Publicado: (2013)

Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan
por: Saleem, Ali Faisal, et al.
Publicado: (2017)

A randomized Phase I/II study to evaluate safety and reactogenicity of a heat-stable rotavirus vaccine in healthy adults followed by evaluation of the safety, reactogenicity, and immunogenicity in infants
por: Kanchan, Vibhu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bq9vsjea49j4n8p0n2e44nfo64